background: clopidogrel is one of the most commonly prescribed drugs to prevent ischemic events following coronary syndromes or stent placement. however, impaired responses to therapy as well as resistance are also reported. genetic variants play an important role in clopidogrel biotransformation to its active metabolite that may subsequently influence the clopidogrel antiplatelet effect. the o...

OBJECTIVE The inhibitory response to clopidogrel considerably varies among individuals and clopidogrel resistance is a risk factor for thrombotic events in patients with cardiovascular disease. Based on the platelet aggregation evaluated by the VerifyNow P2Y12 Assay, the present study investigated clopidogrel resistance and the effect of cilostazol addition. METHODS We measured the ability of...

Atherosclerotic heart disease includes acute coronary syndromes and hyperlipidmia. The prescription of patients with atherosclerotic heart disease mostly contains atorvastatin and clopidogrel. Aim of this study is to estimate clinical pharmacokinetic interaction between atorvastatin and clopidogrel in atherosclerotic heart disease patients. This study was conducted by estimating the carboxylic ...

in this paper a fast and novel stability-indicating ultra fast lc method for separation and estimation of impurities in clopidogrel and aspirin in their combined tablet dosage form and omeprazole was developed. the separation of usp related substances of clopidogrel (a, b and c), aspirin (d), omeprazole (a, b and c) and few other unknown impurities was detected by using ultra fast liquid chroma...

INTRODUCTION Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. OBJECTIVE Identify predictors of clopidogrel following CABG. METHODS We evaluated 5404 patients who underwent CABG between 2000 and 2009 at Duke University Medical Center. We excluded patients undergoing concomitant val...

BACKGROUND Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. There is increasing interest in 'clopidogrel resistance'. OBJECTIVES To determine whether 'clopidogrel resistance' is accounted for by a pre-existent variability in platelet response to ADP. METHODS Platelet response to 20 microm ADP was analyzed by four inde...

BACKGROUND The optimal time delay between last clopidogrel dose and surgery is controversial. The aim of the present study was to analyze the impact of preoperative clopidogrel on the need for blood transfusions with reference to the proper timing of discontinuation. METHODS AND RESULTS Between January 2005 and December 2010, 1,947 consecutive patients undergoing coronary surgery were enrolle...

Objective. To demonstrate on a clinical example the importance of conducting pharmacogenetic testing in patients with ischemic stroke receiving clopidogrel order to identify polymorphic carriage CYP2C19*17 (C806T, rs12248560). Materials and methods. A laboratory examination 121 was carried out, polymorphism rs12248560) associated an increase effectiveness clopidogrel, low residual platelet reac...

Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influen...

BACKGROUND Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may still be ignorant of those DDIs when clopidogrel is a precipitant drug, the factors determining the degree of DDIs, and corresponding ...